Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

Asselah T, Lee SS, Yao BB, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(1):45-51.

Publication Type:

Journal Article

Authors:

Asselah, T; Lee, S.S.; Yao, B.B.; et, al

Source:

Lancet Gastroenterol Hepatol, Volume 4, Issue 1, p.45-51 (2019)

Cited On:

Treatment-Naive Genotype 5 or 6

Export Citation:

RIS Format

Top